Indivior PLC (NASDAQ:INDV – Get Free Report)’s stock price gapped down prior to trading on Friday . The stock had previously closed at $11.09, but opened at $10.66. Indivior shares last traded at $10.83, with a volume of 410,034 shares trading hands.
Wall Street Analyst Weigh In
INDV has been the subject of several recent research reports. Craig Hallum lowered their price target on Indivior from $37.00 to $24.00 and set a “buy” rating on the stock in a report on Wednesday, July 10th. Piper Sandler assumed coverage on Indivior in a research report on Tuesday, July 23rd. They set an “overweight” rating and a $22.00 price objective for the company.
Check Out Our Latest Stock Report on Indivior
Indivior Stock Down 4.1 %
Indivior (NASDAQ:INDV – Get Free Report) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.40 by $0.04. Indivior had a negative net margin of 12.29% and a negative return on equity of 654.82%. The firm had revenue of $299.00 million during the quarter, compared to analysts’ expectations of $285.90 million. On average, sell-side analysts anticipate that Indivior PLC will post 1.74 EPS for the current fiscal year.
Institutional Trading of Indivior
A number of institutional investors have recently modified their holdings of INDV. Vanguard Group Inc. lifted its stake in shares of Indivior by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 5,899,190 shares of the company’s stock valued at $90,081,000 after purchasing an additional 52,836 shares during the period. Norges Bank purchased a new stake in shares of Indivior during the 4th quarter worth approximately $36,011,000. Toronto Dominion Bank grew its holdings in shares of Indivior by 58.0% in the 1st quarter. Toronto Dominion Bank now owns 2,094,865 shares of the company’s stock worth $44,872,000 after acquiring an additional 769,000 shares during the period. Premier Fund Managers Ltd increased its stake in Indivior by 17.8% in the 4th quarter. Premier Fund Managers Ltd now owns 850,980 shares of the company’s stock valued at $12,901,000 after purchasing an additional 128,611 shares in the last quarter. Finally, UBS Group AG increased its stake in Indivior by 71.9% in the 4th quarter. UBS Group AG now owns 826,130 shares of the company’s stock valued at $12,615,000 after purchasing an additional 345,556 shares in the last quarter. 60.33% of the stock is currently owned by hedge funds and other institutional investors.
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Read More
- Five stocks we like better than Indivior
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- Market Cap Calculator: How to Calculate Market Cap
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- How to Start Investing in Real Estate
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.